1. Report on Drug Safety and the US FDA by the Institute of Medicine

   • Anthony W. Fox

   Commentary 24 August 2012 Pages: 289 - 291

2. Human Volunteer Studies — Safety Considerations in an Era of Highly Active Biological Agents

   • Noel J. C. Snell

   Commentary 24 August 2012 Pages: 293 - 296

3. Paediatric Assessment

   • Christopher-Paul Milne

   Current Opinion 24 August 2012 Pages: 297 - 301

   

4. Translational Science in Medicine

   • Martin Wehling

   Current Opinion 24 August 2012 Pages: 303 - 310

   

5. Critical Considerations in Drug Development in Ethnically Diverse Populations

   • Vidal Benatar
   • Samuel Lévy

   Review Article 24 August 2012 Pages: 311 - 316

   

6. Local Clinical Trial Approval Times in the UK

   • Paul Chester
   • Sadiah Aalam
   • Anne Dornhorst

   Original Research Article 24 August 2012 Pages: 317 - 320

   

7. 7th Annual European Congress of Rheumatology

   • Fiona Cameron
   • Sam Crofskey

   Meeting Report 24 August 2012 Pages: 321 - 326

8. Forum

   Update 24 August 2012 Pages: 327 - 330

9. Summary of Recent Deal Activity

   Update 24 August 2012 Pages: 331 - 339

   

10. Major Pharmaceutical Conferences

    Update 24 August 2012 Pages: 341 - 342

    

11. Society of Pharmaceutical Medicine

    SPM News 24 August 2012 Pages: 343 - 343